6-(3-morpholin-4-yl-propionyl)-4H-benzo[1,4]oxazin-3-one | 30150-30-2

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 6-(3-morpholin-4-yl-propionyl)-4H-benzo[1,4]oxazin-3-one
• 英文别名: 6-(3-morpholin-4-ylpropanoyl)-4H-1,4-benzoxazin-3-one
• CAS: 30150-30-2
• 化学式: C₁₅H₁₈N₂O₄
• 分子量: 290.319
• InChiKey: ADXMCRJJLPDQPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] PURINONE COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS PURINONES COMME INHIBITEURS DE KINASE
  申请人：PHARMACYCLICS INC

  公开号：WO2015002894A1

  公开（公告）日：2015-01-08

  Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  披露了形成与布鲁顿酪氨酸激酶（Btk）共价键的化合物。还描述了Btk的不可逆抑制剂。另外，还描述了Btk的可逆抑制剂。还披露了包括该化合物的药物组合物。公开了使用Btk抑制剂的方法，单独或与其他治疗剂联合使用，用于治疗自身免疫性疾病或状况、异体免疫性疾病或状况、癌症，包括淋巴瘤，以及炎症性疾病或状况。
• Intracellular Kinase Inhibitors
  申请人：Flynn A. Gary

  公开号：US20070293499A1

  公开（公告）日：2007-12-20

  Intracellular kinase inhibitors and their therapeutic uses for patients with T cell malignancies, B cell malignancies, autoimmune disorders, and transplanted organs.

  细胞内激酶抑制剂及其在T细胞恶性肿瘤、B细胞恶性肿瘤、自身免疫性疾病和移植器官患者中的治疗用途。
• INTRACELLULAR KINASE INHIBITORS
  申请人：Flynn Gary A.

  公开号：US20110281850A1

  公开（公告）日：2011-11-17

  Intracellular kinase inhibitors and their therapeutic uses for patients with T cell malignancies, B cell malignancies, autoimmune disorders, and transplanted organs.

  细胞内激酶抑制剂及其治疗T细胞恶性肿瘤、B细胞恶性肿瘤、自身免疫性疾病和移植器官的用途。
• PURINONE COMPOUNDS AS KINASE INHIBITORS
  申请人：PHARMACYCLICS LLC

  公开号：US20160168149A1

  公开（公告）日：2016-06-16

  Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了一些能够与布鲁顿酪氨酸激酶（Btk）形成共价键的化合物。同时还描述了Btk的不可逆抑制剂。此外，还描述了Btk的可逆抑制剂。本文还披露了包括这些化合物的制药组合物。本文披露了使用Btk抑制剂的方法，单独或与其他治疗剂联合使用，用于治疗自身免疫疾病或病况、异体免疫疾病或病况、癌症（包括淋巴瘤）和炎症性疾病或病况。
• BTK INHIBITORS FOR THE TREATMENT OF CNS MALIGNANCIES
  申请人：Pharmacyclics LLC

  公开号：US20160008366A1

  公开（公告）日：2016-01-14

  Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of CNS malignancies.

  本文描述了不可逆的Btk抑制剂化合物，以及使用这些不可逆抑制剂治疗中枢神经系统恶性肿瘤的方法。